Q-omics provides the consensus-scored TBX3 profile across patient tissues and cancer cell-line models. TBX3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TBX3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TBX3 RNA expression shows 18,219 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where TBX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX3 survival associations across molecular data types. TBX3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX3 RNA expression–survival associations across cancer types. High TBX3 expression shows unfavorable associations in UVM, KIRP and ACC, but favorable associations in UCS, BLCA and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TBX3 RNA expression.
This table summarizes TBX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX3 shows lower tumor expression in KIRC, LUAD, KIRP and KICH and higher tumor expression in COAD and READ. The KIRC box plot shows higher TBX3 RNA expression in normal versus tumor tissue (log2 FC = −2.123, t-test p < 0.001).
This table shows molecular features associated with TBX3 in patient tissues and cancer cell lines. In patient samples, TBX3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
